Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00093002
Status:
COMPLETED
Last Update Posted:
2008-06-12
First Post:
2004-09-28
Brief Title:
Fulvestrant FASLODEX as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomized Open-Label Multicenter Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant FASLODEX 500 mg With Fulvestrant FASLODEX 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer T2 3 4b N0-3 M0
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose exposure degree of reduction in tumor markers and efficacy in postmenopausal women with estrogen receptor positive disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| D6997C00003 | None | None | None |